NECLIFE vs STAR: Stock Comparison
STRIDES PHARMA SCI is the larger company by market capitalisation. NECTAR LIFESCIENCES shows a lower P/E and lower leverage, while STRIDES PHARMA SCI shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NECLIFE leads 3; STAR leads 7 of 12
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NECLIFE | STAR |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NECLIFE | STAR |
|---|---|---|
| Live Price | ₹10.3 | ₹990 |
| Day Change | -0.29% | -9.79% |
| Volume | 13,046 | 4.7 L |
| 52-Week High | ₹21.4 | ₹1,260.9 |
| 52-Week Low | ₹9.3 | ₹768.65 |
| Distance from 52W High | -51.87% | -21.48% |
Valuation
| Metric | NECLIFE | STAR |
|---|---|---|
| Market Cap | ₹200 Cr | ₹9,431 Cr |
| P/E Ratio | 0x | 16.5x |
| P/B Ratio | 0.4x | 3.26x |
| EPS | ₹-0.79 | ₹17.02 |
| Book Value | ₹29.97 | ₹341.68 |
| Dividend Yield | 0% | 0.46% |
Growth
| Metric | NECLIFE | STAR |
|---|---|---|
| Revenue Growth (TTM YoY) | -3.41% | 11.2% |
| EPS Growth (TTM YoY) | 0% | 54.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | NECLIFE | STAR |
|---|---|---|
| ROE | -9.85% | 5.59% |
| ROCE | -8.89% | 4.43% |
| Net Margin | -11.28% | 10.58% |
| Operating Margin | — | 14.53% |
| Debt to Equity | 0x | 0.35x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | NECLIFE | STAR |
|---|---|---|
| Promoter Holding | 51.84% | 29%▲ 1.09 pp |
| FII Holding | 0.5% | 27.98%▼ 0.41 pp |
| DII Holding | 3.9%▲ 0.16 pp | 15.51%▲ 0.1 pp |
| Public Holding | 43.74%▼ 0.15 pp | 27.51%▼ 0.77 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NECTAR LIFESCIENCES and STRIDES PHARMA SCI.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.